Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers

Journal of Biomedical Science

Volumn 14, Issue 3, 2007, Pages 373-381

  Bao, Li Hong ^a   Sakaguchi, Hideki ^a   Fujimoto, Jiro ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Metastasis; Osteopontin; Ovarian cancer; Prognosis

Indexed keywords

MARKER; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CELL NUCLEUS INCLUSION BODY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MULTIVARIATE ANALYSIS; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; STROMA CELL; SURVIVAL RATE; TUMOR; TUMOR GROWTH; TUMOR VOLUME;

BIOLOGICAL MARKERS; FEMALE; HUMANS; NEOPLASM METASTASIS; OSTEOPONTIN; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249807931     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9143-1     Document Type: Article

References (39)

1. Senger D.R., Wirth D.F., Hynes R.O., (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16: 885-893
2. Craig A.M., Denhardt D.T., (1991) The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene 100: 163-171
3. Denhardt D.T., Guo X., (1993) Osteopontin: a protein with diverse functions. Faseb. J. 7: 1475-1482
4. Denhardt D.T., Noda M., (1998) Osteopontin expression and function: role in bone remodeling. J. Cell. Biochem. Suppl. 30-31: 92-102
5. O'Regan A., Berman J.S., (2000) Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 81: 373-390
6. Weber G.F., (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta. 1552: 61-85
7. Hijiya N., Setoguchi M., Matsuura K., Higuchi Y., Akizuki S., Yamamoto S., (1994) Cloning and characterization of the human osteopontin gene and its promoter. Biochem. J. 303: 255-262
8. Tuck A.B., O'Malley F.P., Singhal H., Tonkin K.S., Harris J.F., Bautista D., Chambers A.F., (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med. 121: 578-584
9. Tuck A.B., O'Malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., Saad Z., Doig G.S., Chambers A.F., (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 79: 502-508
10. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., Chambers A.F., (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18: 4237-4246
11. Rudland P.S., Platt-Higgins A., El-Tanani M., De Silva Rudland S., Barraclough R., Winstanley J.H., Howitt R., West C.R., (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 62: 3417-3427
12. Shijubo N., Uede T., Kon S., Maeda M., Segawa T., Imada A., Hirasawa M., Abe S., (1999) Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 160: 1269-1273
13. Chambers A.F., Wilson S.M., Kerkvliet N., O'Malley F.P., Harris J.F., Casson A.G., (1996) Osteopontin expression in lung cancer. Lung Cancer 15: 311-323
14. Schneider S., Yochim J., Brabender J., Uchida K., Danenberg K.D., Metzger R., Schneider P.M., Salonga D., Holscher A.H., Danenberg P.V., (2004) Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin. Cancer Res. 10: 1588-1596
15. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., Farach-Carson C.M., Studer U.E., Chung L.W., (1999) Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. 5: 2271-2277
16. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., Yeatman T.J., (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl. Cancer. Inst. 94: 513-521
17. Kim J.H., Skates S.J., Uede T., Wong K.K., Schorge J.O., Feltmate C.M., Berkowitz R.S., Cramer D.W., Mok S.C., (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. Jama 287: 1671-1679
18. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., Hellstrom I., Mok S.C., Liu J., Bast Jr. R.C., (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99: 267-277
19. Nakae M., Iwamoto I., Fujino T., Maehata Y., Togami S., Yoshinaga M., Douchi T., (2006) Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 32: 309-314
20. Brakora K.A., Lee H., Yusuf R., Sullivan L., Harris A., Colella T., Seiden M.V., (2004) Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol. Oncol. 93: 361-365
21. Schorge J.O., Drake R.D., Lee H., Skates S.J., Rajanbabu R., Miller D.S., Kim J.H., Cramer D.W., Berkowitz R.S., Mok S.C., (2004) Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin. Cancer Res. 10: 3474-3478
22. Ye B., Skates S., Mok S.C., Horick N.K., Rosenberg H.F., Vitonis A., Edwards D., Sluss P., Han W.K., Berkowitz R.S., Cramer D.W., (2006) Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 12: 432-441
23. Benedet J.L., Bender H., Jones H. 3rd, Ngan H.Y., Pecorelli S., (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 70: 209-262
24. McCarty K.S. Jr., Miller L.S., Cox E.B., Konrath J., McCarty Sr. K.S., (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 109: 716-721
25. Bradford M.M., (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254
26. Ue T., Yokozaki H., Kitadai Y., Yamamoto S., Yasui W., Ishikawa T., Tahara E., (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer 79: 127-132
27. Tuck A.B., Elliott B.E., Hota C., Tremblay E., Chambers A.F., (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor [14]. J. Cell Biochem. 78: 465-475
28. Wu Y., Denhardt D.T., Rittling S.R., (2000) Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br. J. Cancer 83: 156-163
29. Adwan H., Bauerle T.J., Berger M.R., (2004) Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene. Ther. 11: 109-120
30. Behrend E.I., Craig A.M., Wilson S.M., Denhardt D.T., Chambers A.F., (1994) Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 54: 832-837
31. O'Neill C.J., Deavers M.T., Malpica A., Foster H., McCluggage W.G., (2005) An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am. J. Surg. Pathol. 29: 1034-1041
32. Fisher L.W., Jain A., Tayback M., Fedarko N.S., (2004) Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin. Cancer Res. 10: 8501-8511
33. Wai P.Y., Kuo P.C., (2004) The role of Osteopontin in tumor metastasis. J. Surg. Res. 121: 228-241
34. Maki M., Hirota S., Kaneko Y., Morohoshi T., (2000) Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol. Int. 50: 531-535
35. Tiniakos D.G., Yu H., Liapis H., (1998) Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum. Pathol. 29: 1250-1254
36. Fujimoto J., Sakaguchi H., Aoki I., Khatun S., Tamaya T., (2001) Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br. J. Cancer 85: 313-316
37. Fujimoto J., Aoki I., Toyoki H., Khatun S., Sato E., Sakaguchi H., Tamaya T., (2004) Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 66: 420-428
38. Gotoh M., Notoya K., Ienaga Y., Kawase M., Makino H., (2002) Enhancement of osteogenesis in vitro by a novel osteoblast differentiation-promoting compound, TAK-778, partly through the expression of Msx2. Eur. J. Pharmacol. 451: 19-25
39. Pan H.W., Ou Y.H., Peng S.Y., Liu S.H., Lai P.L., Lee P.H., Sheu J.C., Chen C.L., Hsu H.C., (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127